Sep 26, 2016 at 14:38 | Source: Moneycontrol.com
With maintaining neutral rating on Glaxosmithkline Pharmaceutical, Credit Suisse slashed target price to Rs 2,850 as it continues to struggle with price control & supply constraints in some products. It also reduced FY17 earnings per share by 41 percent.
Sep 26, 2016 at 11:55 | Source: Moneycontrol.com
Credit Suisse has maintained its outperform rating on Larsen & Toubro on likely execution pick up, strong cash flows on peaking inventory, subsidiaries support and working capital with reasonable valuations. It has raised target price to Rs 1,925 (from Rs 1,825) per share and changed FY17-19 earnings per share by -1 percent to +2 percent.
Sep 26, 2016 at 10:33 | Source: CNBC-TV18
Abhay Laijawala of Deutsche Bank says with record Kharif output likely to give significant boost to rural consumption sentiment and other factors such as 7th Central Pay Commission also supporting aggregate demand in the economy, it will likely result in consensus upgrades to earnings of consumer and rural interfacing sectors and stocks.
Sep 26, 2016 at 08:38 | Source: Moneycontrol.com
Morgan Stanley prefers Axis Bank structurally over ICICI Bank. It expects Axis Bank to earn 400-500 basis points higher ROE than ICICI Bank. It says ICICI Bank should book capital gain of Rs 5700 crore in Q2.
Sep 23, 2016 at 12:09 | Source: CNBC-TV18
Bharat Financial Inclusion can see 35-40 percent growth in earnings over the next 2-3 years but the stocks valuations are currently steep says Santosh Singh of Haitong Securities.
Sep 23, 2016 at 09:50 | Source: CNBC-TV18
While the current market is driven by liquidity, it will not last forever and earnings will have to improve for growth, Sridhar Sivaram, Investment Director at Enam Holdings told CNBC-TV18.
Sep 22, 2016 at 08:52 | Source: CNBC-TV18
Everything is falling right in place for the Indian markets so the uptrend is likely to continue in the near term feels Vikas Khemani of Edelweiss Financial Services. He believes valuations are reasonable right now and investors would be positively surprised with the earnings growth in coming quarters.
Sep 21, 2016 at 14:57 | Source: Moneycontrol.com
The government now plans to switch to a capital and revenue-spending classifications. This will help create a clear and effective link between the governments earnings, spending and outcomes.
Sep 20, 2016 at 15:36 | Source: CNBC-TV18
Lypsa Gems is going to issue 21 lakh fresh shares to investors at Rs 81 per share. Promoter stake will fall to 33 percent from 36 percent post issuance of shares.
Sep 20, 2016 at 10:02 | Source: Moneycontrol.com
Bank of America Merrill Lynch (BoAML) has maintained its buy rating on Aurobindo Pharma on expectations of strong 23 percent earnings per share (EPS) CAGR over FY16-18, especially after USFDA's successful inspection of unit IV plant at Andhra Pradesh and establishment inspection report for Penem facilities.